Molecular Navigation of Targeted Therapies
Theranostics Health’s technologies are of particular use for companies that develop molecular targeted therapies as they allow insights into the presence and the phospho-activation status of therapeutic targets, their downstream signaling pathways, and potential survival or adaptive mechanisms within the targeted cell populations of therapeutic interest.
Reverse-phase Protein Microarray
The Reverse-phase Protein Microarray (RPMA) platform is a flexible, high-density protein lysate microarray that enables sensitive, non-subjective, quantitative, calibrated, multiplexed analysis of cellular proteins from a limited amount of starting sample, such as small cell culture samples or clinical specimens. In comparison to Western blot analysis, the amount of protein typically required for one Western lane is sufficient to analyze hundreds of different proteins and their post-translational modifications when utilizing the RPMA platform.
Broad Diversity of Biological Samples
The RPMA platform can utilize protein lysates obtained from a broad range of biological samples:
- Preclinical Research Models: Cell and Xenograft Samples
- Surrogate Marker Systems: Blood, Skin and Hair Follicles
- Clinical Biopsy Samples: Excised Tissues and Core Needle Biopsies
Laser Capture Microdissection
To address the issue of tissue heterogeneity, Theranostics Health offers pathologist-directed Laser Capture Microdissection (LCM) services for isolating specific cell populations from the surrounding tissue. When LCM and RPMA technologies are utilized in an integrated manner, one can obtain the specificity of conventional immunochemistry analysis (via LCM selectivity) with high throughput proteomic pathway analysis on clinical samples.
Pre-analytical Sample Handling
The RPMA platform can utilize protein lysate materials from samples subjected to common preservation methods such as flash-freezing or formalin-fixed, paraffin-embedding (FFPE). In addition, a proprietary, room-temperature fixative for preserving tissue/cell morphology and phosphoprotein status is also currently in development.